Primary Immune Deficiency Treatment Consortium (PIDTC) update

Journal of Allergy and Clinical Immunology

Volumn 138, Issue 2, 2016, Pages 375-385

  Griffith, Linda M ^a   Cowan, Morton J ^b   Notarangelo, Luigi D ^c   Kohn, Donald B ^d   Puck, Jennifer M ^b   Shearer, William T ^e   Burroughs, Lauri M ^f   Torgerson, Troy R ^f   Decaluwe, Hélène ^g   Haddad, Elie ^g  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Allogeneic hematopoietic cell transplantation; clinical trial; gene therapy; primary immunodeficiency

Indexed keywords

ARTICLE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); EUROPEAN; HEALTH EDUCATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DEFICIENCY; INTERPERSONAL COMMUNICATION; MEDICAL SPECIALIST; NEWBORN; NEWBORN SCREENING; NORTH AMERICAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RARE DISEASE; SEVERE COMBINED IMMUNODEFICIENCY; T LYMPHOCYTE; THYMUS; TREATMENT INDICATION; WISKOTT ALDRICH SYNDROME; WORKSHOP; ANIMAL; HEALTH SERVICE; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTERSECTORAL COLLABORATION;

ANIMALS; CLINICAL STUDIES AS TOPIC; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTERSECTORAL COLLABORATION; VOLUNTARY HEALTH AGENCIES;

EID: 84976509725     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.01.051     Document Type: Article

References (58)

1. 1 Picard, C., Al-Herz, W., Bousfiha, A., Casanova, J.-L., Chatila, T., Conley, M.E., et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency 2015. J Clin Immunol 35 (2015), 696–726.
2. 2 Bousfiha, A., Jeddane, L., Al-Herz, W., Ailal, F., Casanova, J.-L., Chatila, T., et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol 35 (2015), 727–738.
3. 3 Griffith, L.M., Cowan, M.J., Kohn, D.B., Notarangelo, L.D., Puck, J.M., Schultz, K.R., et al. Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. J Allergy Clin Immunol 122 (2008), 1087–1196.
4. 4 Griffith, L.M., Cowan, M.J., Kohn, D.B., Notarangelo, L.D., Puck, J.M., Pai, S.-Y., et al. Primary Immune Deficiency Treatment Consortium (PIDTC) report. J Allergy Clin Immunol 133 (2014), 335–347.
5. 5 Rare Diseases Act of 2002, Pub L No. 107-280 (2002).
6. 6 Notarangelo, L.D., Primary immunodeficiencies. J Allergy Clin Immunol 125:suppl (2010), S182–S194.
7. 7 Kohn, D.B., Eliminating SCID row: new approaches to SCID. Hematology Am Soc Hematol Educ Program 2014 (2014), 475–480.
8. 8 Marciano, B.E., Spalding, C., Fitzgerald, A., Mann, D., Brown, T., Osgood, S., et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis 60 (2015), 1176–1183.
9. 9 Gennery, A., Severe infections in patients with chronic granulomatous disease. Clin Infect Dis 60 (2015), 1184–1185.
10. 10 Worth, A.J., Thrasher, A.J., Current and emerging treatment options for Wiskott-Aldrich syndrome. Expert Rev Clin Immunol 11 (2015), 1015–1032.
11. 11 Sullivan, K.E., Puck, J.M., Notarangelo, L.D., Fuleihan, R., Caulder, T., Wang, C., et al. USIDNET: a strategy to build a community of clinical immunologists. J Clin Immunol 34 (2014), 428–435.
12. 12 Pai, S.-Y., Logan, B.R., Griffith, L.M., Buckley, R.H., Parrott, R.E., Dvorak, C.C., et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med 371 (2014), 434–446.
13. 13 Kwan, A., Abraham, R.S., Currier, R., Brower, A., Andruszewski, K., Abbott, J.K., et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 312 (2014), 729–738.
14. 14 Dvorak, C.C., Hassan, A., Slatter, M.A., Honig, M., Lankester, A.C., Buckley, R.H., et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol 134 (2014), 935–943.
15. 15 Savic, R.M., Cowan, M.J., Dvorak, C.C., Pai, S.Y., Pereira, L., Bartelink, I.H., et al. Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 19 (2013), 1608–1614.
16. 16 Long-Boyle, J.R., Savic, R., Yan, S., Bartelink, I., Musick, L., French, D., et al. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Ther Drug Monit 37 (2015), 236–245.
17. 17 Kwan, A., Hu, D., Song, M., Gomes, H., Brown, D.R., Bourque, T., et al. Successful newborn screening for SCID in the Navajo Nation. Clin Immunol 158 (2015), 29–34.
18. 18 Shearer, W.T., Dunn, E., Notarangelo, L.D., Dvorak, C.C., Puck, J.M., Logan, B.R., et al. Establishing diagnostic criteria for severe combined immunodeficiency disease (SCID), leaky SCID, and Omenn syndrome: the Primary Immune Deficiency Treatment Consortium experience. J Allergy Clin Immunol 133 (2014), 1092–1098.
19. 19 Dvorak, C.C., Cowan, M.J., Logan, B.R., Notarangelo, L.D., Griffith, L.M., Puck, J.M., et al. The natural history of children with severe combined immunodeficiency: baseline features of the first fifty patients of the Primary Immune Deficiency Treatment Consortium prospective study 6901. J Clin Immunol 33 (2013), 1156–1164.
20. 20 Heimall, J., Logan, B.R., Cowan, M.J., Notarangelo, L.D., Griffith, L.M., Puck, J., et al. Early hematopoietic cell transplant (HCT) outcomes of children with severe combined immunodeficiency disease (SCID): the first seventy four patients of the Primary Immune Deficiency Treatment Consortium (PIDTC) prospective study 6901. Biol Blood Marrow Transplant 21:suppl (2015), S289–S291.
21. 21 Slatter, M.A., Rao, K., Amrolia, P., Flood, T., Abinun, M., Hambleton, S., et al. Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience. Blood 117 (2011), 4367–4375.
22. 22 Slatter, M.A., Boztug, H., Potschger, U., Sykora, K.-W., Lankester, A., Yaniv, I., et al. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant 50 (2015), 1536–1541.
23. 23 Burroughs, L.M., Nemecek, E.R., Torgerson, T.R., Storer, B.E., Talano, J.A., Domm, J., et al. Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial. Biol Blood Marrow Transplant 12 (2014), 1996–2003.
24. 24 Haddad, E., Leroy, S., Buckley, R.H., B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment?. J Allergy Clin Immunol 131 (2013), 994–1000.
25. 25 Cowan, M.J., Gennery, A.R., Radiation-sensitive severe combined immunodeficiency: the arguments for and against conditioning before hematopoietic cell transplantation—what to do?. J Allergy Clin Immunol 136 (2015), 1178–1185.
26. 26 Czechowicz, A., Kraft, D., Weissman, I.L., Bhattacharya, D., Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318 (2007), 1296–1299.
27. 27 Straathof, K.C., Rao, K., Eyrich, M., Hale, G., Bird, P., Berrie, E., et al. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 374 (2009), 912–920.
28. 28 Airoldi, I., Bertaina, A., Prigione, I., Zorzoli, A., Pagliara, D., Cocco, C., et al. Gamma-delta T-cell reconstitution after HLA-haploidentical hematopoietic transplantation depleted of TCR-alpha-beta+ / CD19+ lymphocytes. Blood 125 (2015), 2349–2358.
29. 29 Fuchs, E.J., Haploidentical transplantation for hematologic malignancies: where do we stand?. Hematology Am Soc Hematol Educ Program 2012 (2012), 230–236.
30. 30 Kanakry, C.G., Tsai, H.L., Bolanos-Meade, J., Smith, B.D., Gojo, I., Kanakry, J.A., et al. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood 124 (2014), 3817–3827.
31. 31 Kuo, C.Y., Kohn, D.B., Gene therapy for the treatment of primary immune deficiencies. Curr Allergy Asthma Rep, 16, 2016, 39.
32. 32 Williams, D.A., Thrasher, A.J., Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases. Stem Cells Transl Med 3 (2014), 636–642.
33. 33 Hacein-Bey-Abina, S., Hauer, J., Lim, A., Picard, C., Wang, G.P., Berry, C.C., et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 363 (2010), 355–364.
34. 34 Gaspar, H.B., Parsley, K.L., Howe, S., King, D., Gilmour, K.C., Sinclair, J., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004), 2181–2187.
35. 35 Hacien-Bey-Abina, S., Pai, S.Y., Gaspar, H.B., Armant, M., Berry, C.C., Blanche, S., et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 371 (2014), 1407–1417.
36. 36 Kang, E.M., Marciano, B.E., DeRavin, S.S., Zarember, K.A., Holland, S.M., Malech, H.L., Chronic granulomatous disease: overview and hematopoietic stem cell transplantation. J Allergy Clin Immunol 127 (2011), 1319–1326.
37. 37 Moratto, D., Giliani, S., Bonfim, C., Mazzolari, E., Fischer, A., Ochs, H.D., et al. Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study. Blood 118 (2011), 1675–1684.
38. 38 Conley, M.E., Saragoussi, D., Notarangelo, L., Etzoni, A., Casanova, J.-L., PAGID; ESID. An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. Clin Immunol 109 (2003), 272–277.
39. 39 Becker-Herman, S., Meyer-Bahlburg, A., Schwartz, M.A., Jackson, S.W., Hudkins, K.L., Liu, C., et al. WASp-deficient B cells play a critical, cell-intrinsic role in triggering autoimmunity. J Exp Med 208 (2011), 2033–2042.
40. 40 Dumont-Lagacé, M., Brochu, S., St-Pierre, C., Perreault, C., Adult thymic epithelium contains nonsenescent label-retaining cells. J Immunol 192 (2014), 2219–2226.
41. 41 Krenger, W., Blazar, B.R., Hollander, G.A., Thymic T-cell development in allogeneic stem cell transplantation. Blood 117 (2011), 6768–6776.
42. 42 Li, B., Li, J., Devlin, B.H., Markert, M.L., Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol 140 (2011), 244–259.
43. 43 Markert, M.L., Devlin, B.H., McCarthy, E.A., Thymus transplantation. Clin Immunol 135 (2010), 236–246.
44. 44 Ji, H., Ehrlich, L.I., Seita, J., Murakami, P., Doi, A., Lindau, P., et al. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature 467 (2010), 338–342.
45. 45 Inlay, M.A., Bhattacharya, D., Sahoo, D., Serwold, T., Seita, J., Karsunky, H., et al. Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development. Genes Dev 23 (2009), 2376–2381.
46. 46 Fathman, J.W., Bhattacharya, D., Inlay, M.A., Seita, J., Karsunky, H., Weissman, I.L., Identification of the earliest natural killer cell-committed progenitor in murine bone marrow. Blood 118 (2011), 5439–5447.
47. 47 Smigiel, K.S., Srivastava, S., Stolley, J.M., Campbell, D.J., Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. Immunol Rev 259 (2014), 40–59.
48. 48 Gratz, I.K., Campbell, D.J., Organ-specific and memory Treg cells: specificity, development, function, and maintenance. Front Immunol, 5, 2014, 333.
49. 49 Matthews, A., Zheng, S., DiMenna, L.J., Chaudhuri, J., Regulation of immunoglobulin class-switch recombination: choreography of noncoding transcription, targeted DNA deamination, and long-range DNA repair. Adv Immunol 122 (2014), 1–57.
50. 50 Vuong, B.Q., Herrick-Reynolds, K., Vaidyanathan, B., Pucella, J.N., Ucher, A.J., Donghia, N.M., et al. A DNA break- and phosphorylation-dependent positive feedback loop promotes immunoglobulin class-switch recombination. Nat Immunol 14 (2013), 1183–1189.
51. 51 Koehne, G., Hasan, A., Doubrovina, E., Prockop, S., Tyler, E., Wasilewski, G., et al. Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia. Biol Blood Marrow Transplant 21 (2015), 1663–1678.
52. 52 Saglio, F., Hanley, P.J., Bollard, C.M., The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16 (2014), 149–159.
53. 53 Wehr, C., Gennery, A.R., Lindemans, C., Schulz, A., Hoenig, M., Marks, R., et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol 135 (2015), 988–997.e6.
54. 54 Cunningham-Rundles, C., How I treat common variable immunodeficiency. Blood 116 (2010), 7–15.
55. 55 Griffith, L.M., Cowan, M.J., Notarangelo, L.D., Puck, J.M., Buckley, R.H., Candotti, F., et al. Improving cellular therapy for primary immune deficiency diseases: recognition, diagnosis, and management. J Allergy Clin Immunol 124 (2009), 1152–1160.
56. 56 Shah, A.J., Epport, K., Azen, C., Killen, R., Wilson, K., De Clerck, D., et al. Progressive declines in neurocognitive function among survivors of hematopoietic stem cell transplantation for pediatric hematologic malignancies. J Pediatr Hematol Oncol 30 (2008), 411–418.
57. 57 Lin, M., Epport, K., Azen, C., Parkman, R., Kohn, D.B., Shah, A.J., Long-term neurocognitive function of pediatric patients with severe combined immune deficiency (SCID): pre- and post-hematopoietic stem cell transplant (HSCT). J Clin Immunol 29 (2009), 231–237.
58. 58 Grunebaum, E., Cohen, A., Roifman, C.M., Recent advances in understanding and managing adenosine deaminase and purine nucleoside phosphorylase deficiencies. Curr Opin Allergy Clin Immunol 13 (2013), 630–638.